Tokyo, Japan

Shusuke Hashimoto


 

 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Tokyo, JP (1995 - 2013)
  • Minato-ku, JP (2014 - 2015)

Company Filing History:


Years Active: 1995-2015

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Shusuke Hashimoto: Innovator in Pharmaceutical Compounds

Introduction

Shusuke Hashimoto is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic applications. With a total of 13 patents to his name, Hashimoto's work has garnered attention in the scientific community.

Latest Patents

Among his latest patents, Hashimoto has developed a phenanthroindolizidine compound and an NFκB inhibitor containing the same as an active ingredient. This innovative compound exhibits an excellent NFκB inhibitory effect, which is crucial for various therapeutic applications. Additionally, he has created a BCRP/ABCG2 inhibitor, which is a breast cancer resistance protein inhibitor. This BCRP inhibitor contains an acrylonitrile derivative or a salt thereof as its active ingredient.

Career Highlights

Hashimoto has worked with notable companies such as Kabushiki Kaisha Yakult Honsha and Teikoku Hormone Mfg. Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Throughout his career, Hashimoto has collaborated with esteemed colleagues, including Takeshi Matsuzaki and Masato Nagaoka. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Shusuke Hashimoto's contributions to pharmaceutical innovations are noteworthy, and his patents reflect his dedication to advancing medical science. His work continues to impact the industry positively, paving the way for future developments in therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…